Financial Performance - The company's revenue for Q1 2023 was ¥2,063,038,679.08, representing a 22.40% increase compared to ¥1,685,498,423.72 in the same period last year[3] - Net profit attributable to shareholders was ¥718,568,079.44, up 31.12% from ¥548,033,363.89 year-on-year[3] - Basic earnings per share rose to ¥0.107, reflecting a 32.10% increase from ¥0.081 in the same quarter last year[3] - Total operating revenue for the current period reached ¥2,063,038,679.08, a 22.4% increase from ¥1,685,498,423.72 in the previous period[16] - Net profit for the current period was ¥718,266,042.76, representing a 31.4% increase compared to ¥545,987,550.05 in the previous period[17] - Operating profit rose to ¥842,272,279.67, an increase of 30.5% from ¥645,693,141.36 in the previous period[17] - The company reported a total comprehensive income of ¥528,071,210.89, compared to ¥479,205,487.47 in the previous period[17] Cash Flow and Liquidity - The net cash flow from operating activities reached ¥1,070,515,512.59, a significant increase of 157.77% compared to ¥415,302,906.87 in the previous year[3] - Cash flow from operating activities generated a net amount of ¥1,070,515,512.59, significantly up from ¥415,302,906.87 in the previous period[20] - Cash and cash equivalents at the end of the period totaled ¥3,631,414,859.74, compared to ¥2,660,030,335.64 at the end of the previous period[21] - The company's cash and cash equivalents increased to RMB 4,569,595,868.99 from RMB 3,977,425,328.72, representing a growth of about 14.8%[11] - The company reported a significant increase in cash reserves, which may support future investments and operational expansions[11] Assets and Liabilities - Total assets at the end of the reporting period were ¥31,008,256,414.76, a 1.81% increase from ¥30,457,959,495.12 at the end of the previous year[3] - The total liabilities of the company as of March 31, 2023, were RMB 1,666,806,771.14, slightly up from RMB 1,644,618,113.59 at the beginning of the year[13] - The equity attributable to shareholders of the parent company increased to RMB 29,347,122,761.37 from RMB 28,818,712,462.60, reflecting a growth of approximately 1.8%[13] - The company's non-current assets totaled RMB 22,354,391,292.06, up from RMB 21,984,549,673.90, indicating an increase of about 1.7%[12] Research and Development - The company's R&D expenses increased by 33.77% to ¥46,017,682.81, driven by an expansion in research activities[6] - Research and development expenses increased to ¥46,017,682.81, up from ¥34,400,140.41 in the previous period, indicating a focus on innovation[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 123,870, with the largest shareholder holding 26.20% of the shares[8] Other Financial Metrics - The weighted average return on equity improved to 2.47%, up 0.37 percentage points from 2.10% in the previous year[3] - The company experienced a 99.61% decrease in other current assets, primarily due to a reduction in deductible VAT input tax[6] - Accounts receivable decreased to RMB 523,036,139.16 from RMB 707,021,384.74, indicating a decline of approximately 26%[11] - Inventory levels decreased to RMB 3,064,179,372.22 from RMB 3,268,843,130.57, showing a reduction of about 6.3%[12] - The company reported a significant increase in government subsidies, totaling ¥2,427,675.03, although this was a 39.82% decrease compared to the previous year[7] - The company's short-term borrowings and other financial liabilities were not detailed in the provided data, indicating a focus on operational liquidity management[13] - The overall financial health of the company appears stable, with a solid increase in total assets and equity, despite some declines in receivables and inventory levels[14]

Financial Performance - The company's operating revenue for 2022 was ¥6,567,198,581.04, representing a 53.16% increase compared to ¥4,287,726,749.67 in 2021[11]. - The net profit attributable to shareholders for 2022 was ¥1,880,090,066.90, up 45.24% from ¥1,294,510,050.46 in 2021[11]. - The net profit after deducting non-recurring gains and losses was ¥1,826,062,740.20, a 33.40% increase from ¥1,368,820,159.04 in 2021[11]. - The net cash flow from operating activities for 2022 was ¥1,725,596,063.70, reflecting a 33.35% increase compared to ¥1,294,013,219.19 in 2021[11]. - The total assets at the end of 2022 were ¥30,457,959,495.12, an 11.83% increase from ¥27,236,582,048.82 at the end of 2021[11]. - The net assets attributable to shareholders at the end of 2022 were ¥28,818,712,462.60, up 11.26% from ¥25,902,445,517.58 at the end of 2021[11]. - The company reported a weighted average return on equity of 6.87% for 2022, an increase of 1.79 percentage points from 5.08% in 2021[11]. - The company's total revenue for 2022 reached ¥6,567,198,581.04, representing a 53.16% increase compared to ¥4,287,726,749.67 in 2021[41]. - The blood product segment generated ¥6,504,836,891.84, accounting for 99.05% of total revenue, with a year-on-year growth of 51.81%[41]. - The company reported a total operating cost of approximately CNY 3.67 billion, a 77.56% increase from the previous year[45]. Dividend Distribution - The company plans to distribute a cash dividend of 0.30 RMB per 10 shares to all shareholders, with no bonus shares or capital increase from reserves[2]. - The total cash dividend for the year 2022 was RMB 202,223,637.21, which is inclusive of all distribution methods[139]. - The company has no plans for stock dividends or capital reserve transfers in the current profit distribution[139]. - The company’s cash dividend policy complies with relevant laws and regulations, ensuring protection for minority shareholders[138]. Market Position and Growth - The blood product industry is experiencing steady growth due to increased clinical application and market demand, despite external pressures[15]. - The company is a leading player in China's blood products industry, with a comprehensive product range and high plasma utilization rate[22]. - The company has seen a notable increase in market share through collaboration with key opinion leaders in various medical fields, enhancing its brand image and industry leadership[24]. - The company is positioned to benefit from the increasing concentration in the blood products industry, with major players dominating the market[21]. - The company has achieved a record plasma collection volume of over 1,400 tons during the reporting period, marking a historical high[33]. - The company operates 42 plasma collection stations across 11 provinces, ranking among the top in the industry for both station count and plasma collection volume[23]. Research and Development - The company is actively pursuing research and development in hemophilia treatment and exploring new clinical indications for its products[34]. - The company is in the pre-clinical development stage for several new products, including a 10% intravenous immunoglobulin and an activated prothrombin complex, aimed at enhancing product lines and competitiveness[54]. - The company plans to continue its commitment to research and development to drive innovation in blood product solutions[100]. - The company is investing CNY 500 million in R&D for new blood product technologies over the next three years[148]. Operational Efficiency and Management - The company has strengthened its management and operational strategies to enhance plasma source expansion, focusing on both existing and new plasma collection stations[32]. - The company has implemented a comprehensive quality management system, ensuring the safety, quality, and efficiency of its products[35]. - The company has enhanced its internal management efficiency and operational levels, focusing on a high-standard quality management system[38]. - The company aims to optimize resource allocation and improve cost control in its plasma station operations[83]. - The company is focused on expanding its plasma source and improving operational management capabilities[83]. Risks and Challenges - The company faces risks including raw material supply, rising plasma costs, potential product safety issues, and goodwill impairment[2]. - The supply-demand imbalance for raw plasma remains significant, with the number of single plasma collection stations in China being insufficient to meet actual demand[16]. - The company is exposed to currency exchange risks due to its import trade primarily settled in USD and plans to monitor foreign currency transactions to mitigate this risk[91]. Corporate Governance - The company has established a complete and clear internal governance structure, complying with relevant laws and regulations[93]. - The company is committed to enhancing its corporate governance structure by filling independent director positions as required by regulations[101]. - The company continues to strengthen its internal control system to improve governance levels[93]. - The company has made revisions to its governance documents, including the company charter and shareholder meeting rules, to improve operational efficiency[126]. Environmental Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities[146]. - The company has implemented measures to ensure compliance with environmental standards and regulations[146]. - The wastewater treatment facility operates with a process including regulation, acid hydrolysis, and disinfection, ensuring effective pollutant removal[163]. - The company has received multiple environmental approvals for its projects, including a recent wastewater discharge permit valid until December 2023[159]. Strategic Partnerships and Acquisitions - The company is exploring potential mergers and acquisitions to strengthen its market position and expand its product portfolio[100]. - The company has completed two strategic acquisitions in 2022, enhancing its production capacity by 30%[150]. - The company has established exclusive distribution rights for Grifols, S.A. products in China, excluding Hong Kong, Macau, and Taiwan[192]. Employee Management and Welfare - The total number of employees at the end of the reporting period was 3,121, with 618 in the parent company and 2,503 in major subsidiaries[131]. - The company provided additional benefits such as paid leave, annual health checks, and supplementary medical insurance to enhance employee welfare[133]. - The company implemented a performance-based salary adjustment and bonus distribution policy to align organizational goals with individual objectives[133].

2、召开方式：网络远程的方式 3、出席人员：公司董事、总经理徐俊先生，独立董事彭玲女士，副总经理、 董事会秘书刘峥先生、财务负责人陈乐奇先生等。 证券代码：002252 证券简称：上海莱士 公告编号：2023-022 上海莱士血液制品股份有限公司 关于举办2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"公司"）已于2023年4月25日在巨潮资讯 网上披露了《2022年年度报告》等。为便于广大投资者更加全面深入地了解公司 生产经营等情况，公司定于2023年5月8日（星期一）15:00-17:00在全景网举办2022 年度网上业绩说明会，与投资者进行沟通和交流，听取投资者的意见和建议。本 次网上说明会的具体情况如下： 一、 本次业绩说明会安排 1、召开时间：2023年5月8日（星期一）15:00-17:00 （问题征集专题页面二维码） 欢迎广大投资者积极参与本次网上说明会。 特此公告。 上海莱士血液制品股份有限公司 董事会 4、投资者参与方式：投资者可登录全景网"投资者关系互动平台" （https: ...

Group 1: Company Structure and Shareholding - The major shareholder after the restructuring is Jilifu, holding 26.2% of the company [2] - The controlling shareholders remain Keri Tiancheng and Laisi China [2] - The restructuring involved the transfer of 45% GDS shares to the company [2][4] Group 2: Debt Management and Financial Strategy - The controlling shareholder is managing debt through communication with creditors and extending debt terms [3] - There is no active reduction of company shares by the controlling shareholder, with some passive reductions due to creditor actions [3] Group 3: Value Enhancement from Restructuring - The restructuring is expected to optimize the industry structure by expanding into the in-vitro diagnostics field [3] - The introduction of advanced management practices from Jilifu is anticipated to improve operational efficiency and profitability [3] - Collaboration with Jilifu will enhance production quality, technology development, and market presence [3] Group 4: GDS Business Performance - GDS is a leading global manufacturer of blood testing instruments and reagents, with a strong market share in nucleic acid testing [4] - GDS has expanded its product line, including new testing reagents for Zika virus and Babesia [4] - The acquisition of GDS shares is expected to positively impact the company's financial performance [4] Group 5: Plasma Collection and Industry Trends - The company operates 41 plasma collection stations across 11 provinces [5] - The pandemic has temporarily affected plasma collection, but operations have resumed [5] - The blood products industry is expected to maintain stable growth despite challenges from the pandemic [5] Group 6: Sales and Marketing Strategy - The company has shifted to a dual sales model, combining commercial channels with hospital sales [5] - Various marketing strategies are being employed to maximize business growth opportunities [5] - The blood products industry remains robust, with significant potential for clinical application [5]

Group 1: Company Overview - Shanghai Laishi Blood Products Co., Ltd. has four production bases located in Shanghai, Zhengzhou, Hefei, and Wenzhou, covering 11 product categories including albumin, immunoglobulin, and coagulation factors [3]. - The company is one of the few in China capable of extracting six components from plasma and has a comprehensive range of coagulation factor products [3]. - The company has passed GMP certification since November 1998 and is the first in the industry to obtain ISO9001:2000 certification [3]. Group 2: Market Position and Strategy - The company aims to become a leading global player in the blood products industry, focusing on both organic growth and strategic acquisitions [3][4]. - In 2018, the company initiated a major asset restructuring project to acquire 45% equity in GDS, which is essential for controlling product quality and safety [4]. - The company has established a strong brand image, recognized for safety and quality, and has registered products in nearly 20 countries and regions [3]. Group 3: Financial Performance - In the first half of 2019, the net profit attributable to shareholders was CNY 413 million [4]. - The company is experiencing steady growth in terminal sales, with a focus on expanding into new regions such as North China, Southwest, Northeast, and Northwest [4]. Group 4: Industry Trends and Challenges - The actual demand for plasma in China exceeds 14,000 tons, while the total plasma collection in 2018 was over 8,000 tons, indicating a significant supply-demand gap [5]. - The blood products industry is transitioning from a tight supply to a balanced state, with high demand expected to continue [4]. - The consumption structure of blood products in China is heavily weighted towards human albumin and immunoglobulin, which together account for nearly 80% of the market, while the international average for immunoglobulin and coagulation factors exceeds 80% [5].